Genomic Medicine Archives

$FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation$

FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

by Anna Tan | Aug 3, 2018 | Nursing, Pharmacy, Primary Care

On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved the first acute myeloid leukemia treatment. It is the first approved targeted cancer therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML), specifically, those screened...

FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

Recent Posts

Categories